Cybin to Participate in the Jefferies Global Healthcare Conference in London

Audio By Carbonatix

TORONTO--(BUSINESS WIRE)--Nov 12, 2025--

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that George Tziras, Cybin’s Chief Business Officer, will present at the Jefferies Global Healthcare Conference, taking place November 17-20, 2025, in London, UK.

The presentation will be webcast live on Monday, November 17, 2025, at 12:30 p.m. GMT (7:30 a.m. ET). To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a breakthrough Phase 3 clinical-stage neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, and Ireland.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251112401823/en/

CONTACT: Investor Contact:

Josh Barer

astr partners

Managing Director

(908) 578-6478

[email protected]

George Tziras

Chief Business Officer

Cybin Inc.

1-866-292-4601

[email protected]– or –[email protected]

KEYWORD: EUROPE UNITED KINGDOM NORTH AMERICA CANADA

INDUSTRY KEYWORD: NEUROLOGY BIOTECHNOLOGY PHARMACEUTICAL ALTERNATIVE MEDICINE MANAGED CARE HEALTH MENTAL HEALTH CLINICAL TRIALS

SOURCE: Cybin Inc.

Copyright Business Wire 2025.

PUB: 11/12/2025 07:30 AM/DISC: 11/12/2025 07:31 AM

http://www.businesswire.com/news/home/20251112401823/en